NeuroTargeting’s database collects neurological data from around the world: 7 insights

Nashville, Tenn.-based Vanderbilt University researchers created the company, NeuroTargeting, which offers a database for fighting neurological disorders, according to The Tennessean.

Advertisement

Here are seven insights:

 

1. In 2007, engineers Pierre-Francois D’Haese, PhD, and Benoit Dawant, PhD, joined forces with neurosurgeon Peter Konrad, MD, PhD, to create NeuroTargeting.

 

2. At first, the company established brain geomapping software. Now, with a decade’s worth of data, they are focusing on the neurological database.

 

3. NeuroTargeting’s CranialCloud offers physicians access to a patient population beyond their walls, connecting centers around the word.

 

4. Patients may also access CranialCloud to achieve a better understanding of their conditions and be more immersed in their treatment options.

 

5. NeuroTargeting received a National Institutes of Health Small Business Technology Transfer grant of $700,000.

 

6. The company has partnerships with Winston-Salem, N.C.-based Wake Forest University, University of California San Francisco, Columbus-based Ohio State University and the Richmond, Va.-based VA Medical Center.

 

7. NeuroTargeting also entered into contracts with Medtronic and FHC.

 

More articles on spine:
Frailty proves an independent predictor of degenerative spine surgery outcomes: 5 observations
Are neurosurgeon residents losing out on education because of restricted duty hours? 5 thoughts
Is risk of blindness still a major concern of spinal fusion? 5 insights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spine

Advertisement

Comments are closed.